Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel Free BDSX Stock Alerts

Biodesix (BDSX) Competitors

Biodesix logo
$26.63 0.00 (0.00%)
As of 08/21/2026 04:00 PM Eastern
Compare

BDSX vs. CSTL, TALK, GMRS, FLGT, and SRTA

Should you buy Biodesix stock or one of its competitors? Biodesix's main competitors and comparable companies include Castle Biosciences (CSTL), Talkspace (TALK), GMR Solutions (GMRS), Fulgent Genetics (FLGT), and Strata Critical Medical (SRTA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does Biodesix compare to Castle Biosciences?

Castle Biosciences (NASDAQ:CSTL) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Castle Biosciences presently has a consensus price target of $42.00, indicating a potential upside of 22.81%. Biodesix has a consensus price target of $31.33, indicating a potential upside of 17.66%. Given Castle Biosciences' higher probable upside, equities research analysts plainly believe Castle Biosciences is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Castle Biosciences
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.80
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Castle Biosciences has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, Castle Biosciences had 4 more articles in the media than Biodesix. MarketBeat recorded 5 mentions for Castle Biosciences and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.31 beat Castle Biosciences' score of 0.91 indicating that Biodesix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Castle Biosciences
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biodesix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Castle Biosciences has higher revenue and earnings than Biodesix. Castle Biosciences is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Castle Biosciences$344.23M3.04-$24.16M-$0.66N/A
Biodesix$88.50M3.17-$35.26M-$3.17N/A

Castle Biosciences has a net margin of -5.43% compared to Biodesix's net margin of -26.97%. Castle Biosciences' return on equity of -4.15% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Castle Biosciences-5.43% -4.15% -3.45%
Biodesix -26.97%-788.19%-30.33%

92.6% of Castle Biosciences shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 6.1% of Castle Biosciences shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Castle Biosciences beats Biodesix on 11 of the 15 factors compared between the two stocks.

How does Biodesix compare to Talkspace?

Talkspace (NASDAQ:TALK) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

57.4% of Talkspace shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 23.5% of Talkspace shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Talkspace has a beta of 1.1, meaning that its stock price is 10% more volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Talkspace presently has a consensus price target of $5.56, suggesting a potential upside of 5.95%. Biodesix has a consensus price target of $31.33, suggesting a potential upside of 17.66%. Given Biodesix's stronger consensus rating and higher probable upside, analysts plainly believe Biodesix is more favorable than Talkspace.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talkspace
1 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Talkspace had 6 more articles in the media than Biodesix. MarketBeat recorded 7 mentions for Talkspace and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.31 beat Talkspace's score of 0.24 indicating that Biodesix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Talkspace
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biodesix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Talkspace has higher revenue and earnings than Biodesix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Talkspace$228.87M3.84$7.79MN/AN/A
Biodesix$88.50M3.17-$35.26M-$3.17N/A

Talkspace has a net margin of 0.08% compared to Biodesix's net margin of -26.97%. Talkspace's return on equity of 0.17% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Talkspace0.08% 0.17% 0.14%
Biodesix -26.97%-788.19%-30.33%

Summary

Talkspace beats Biodesix on 10 of the 15 factors compared between the two stocks.

How does Biodesix compare to GMR Solutions?

GMR Solutions (NYSE:GMRS) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, GMR Solutions had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for GMR Solutions and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.31 beat GMR Solutions' score of 1.16 indicating that Biodesix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GMR Solutions
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biodesix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biodesix has lower revenue, but higher earnings than GMR Solutions. GMR Solutions is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GMR Solutions$5.88B0.12-$84.27M-$1.56N/A
Biodesix$88.50M3.17-$35.26M-$3.17N/A

GMR Solutions has a net margin of 0.00% compared to Biodesix's net margin of -26.97%. GMR Solutions' return on equity of 0.00% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
GMR SolutionsN/A N/A N/A
Biodesix -26.97%-788.19%-30.33%

GMR Solutions presently has a consensus price target of $18.67, indicating a potential upside of 37.56%. Biodesix has a consensus price target of $31.33, indicating a potential upside of 17.66%. Given GMR Solutions' higher probable upside, research analysts clearly believe GMR Solutions is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GMR Solutions
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.70
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

21.0% of Biodesix shares are owned by institutional investors. 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

GMR Solutions beats Biodesix on 8 of the 15 factors compared between the two stocks.

How does Biodesix compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Fulgent Genetics has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

In the previous week, Fulgent Genetics had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Fulgent Genetics and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.31 beat Fulgent Genetics' score of 1.30 indicating that Biodesix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Fulgent Genetics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biodesix
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Fulgent Genetics currently has a consensus target price of $27.50, indicating a potential upside of 38.19%. Biodesix has a consensus target price of $31.33, indicating a potential upside of 17.66%. Given Fulgent Genetics' higher probable upside, research analysts plainly believe Fulgent Genetics is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Fulgent Genetics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Fulgent Genetics has a net margin of -26.05% compared to Biodesix's net margin of -26.97%. Fulgent Genetics' return on equity of -4.93% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Fulgent Genetics-26.05% -4.93% -4.50%
Biodesix -26.97%-788.19%-30.33%

Biodesix has lower revenue, but higher earnings than Fulgent Genetics. Biodesix is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$322.67M1.70-$60.51M-$2.82N/A
Biodesix$88.50M3.17-$35.26M-$3.17N/A

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Fulgent Genetics beats Biodesix on 11 of the 17 factors compared between the two stocks.

How does Biodesix compare to Strata Critical Medical?

Biodesix (NASDAQ:BDSX) and Strata Critical Medical (NASDAQ:SRTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Biodesix currently has a consensus price target of $31.33, suggesting a potential upside of 17.66%. Strata Critical Medical has a consensus price target of $8.00, suggesting a potential upside of 28.21%. Given Strata Critical Medical's higher possible upside, analysts plainly believe Strata Critical Medical is more favorable than Biodesix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biodesix
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Strata Critical Medical
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.75

Strata Critical Medical has higher revenue and earnings than Biodesix. Strata Critical Medical is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biodesix$88.50M3.17-$35.26M-$3.17N/A
Strata Critical Medical$197.14M2.80$41.35M-$0.04N/A

In the previous week, Biodesix had 1 more articles in the media than Strata Critical Medical. MarketBeat recorded 1 mentions for Biodesix and 0 mentions for Strata Critical Medical. Biodesix's average media sentiment score of 1.31 beat Strata Critical Medical's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company Overall Sentiment
Biodesix Positive
Strata Critical Medical Neutral

Biodesix has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Strata Critical Medical has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 47.4% of Strata Critical Medical shares are held by institutional investors. 23.2% of Biodesix shares are held by insiders. Comparatively, 15.5% of Strata Critical Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Strata Critical Medical has a net margin of 15.71% compared to Biodesix's net margin of -26.97%. Strata Critical Medical's return on equity of -2.97% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Biodesix-26.97% -788.19% -30.33%
Strata Critical Medical 15.71%-2.97%-2.54%

Summary

Strata Critical Medical beats Biodesix on 9 of the 16 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDSX vs. The Competition

Export
MetricBiodesixHealthcare Providers & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$280.95M$9.84B$7.32B$12.82B
Dividend YieldN/A2.55%2.54%10.78%
P/E Ratio-8.4034.38272.9024.25
Price / Sales3.174.95632.6497.63
Price / CashN/A24.6429.0336.90
Price / Book-85.905.4011.256.42
Net Income-$35.26M$309.96M$3.47B$348.89M
7 Day Performance14.54%0.99%2.33%0.57%
1 Month Performance21.05%2.30%7.72%4.90%
1 Year Performance193.67%15.69%25.22%17.06%

Biodesix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDSX
Biodesix
4.3343 of 5 stars		$26.63
flat		$31.33
+17.7%		+193.7%$280.95M$88.50MN/A220
CSTL
Castle Biosciences
3.5323 of 5 stars		$32.74
+1.2%		$42.00
+28.3%		+64.1%$998.07M$344.23MN/A540
TALK
Talkspace
1.9817 of 5 stars		$5.23
-0.3%		$5.56
+6.5%		N/A$875.24M$228.87MN/A500
GMRS
GMR Solutions
4.595 of 5 stars		$12.72
+0.6%		$19.22
+51.1%		N/A$687.01MN/A45.43N/A
FLGT
Fulgent Genetics
3.6266 of 5 stars		$19.10
+0.2%		$27.50
+44.0%		-8.6%$525.00M$322.67MN/A1,315

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BDSX) was last updated on 8/24/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Bank of America grew this stake 139%
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
I found Rolls-Royce at $2 - now I see the same setup again
In 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...
Monument Traders Alliance | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel